In the last trading session, 4.87 million Allogene Therapeutics Inc (NASDAQ:ALLO) shares changed hands as the company’s beta touched 1.05. With the company’s per share price at $2.17 changed hands at -$0.09 or -3.77% during last session, the market valuation stood at $454.99M. ALLO’s last price was a discount, traded about -166.36% off its 52-week high of $5.78. The share price had its 52-week low at $1.32, which suggests the last value was 39.17% up since then.
Analysts gave the Allogene Therapeutics Inc (ALLO) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.56. If we narrow down to specifics, the data shows that 0 out of 6 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended ALLO as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight. Allogene Therapeutics Inc’s EPS for the current quarter is expected to be -0.32.
Allogene Therapeutics Inc (NASDAQ:ALLO) trade information
Instantly ALLO was in red as seen at the end of in last trading. With action 53.90%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 1.88%, with the 5-day performance at 53.90% in the green. However, in the 30-day time frame, Allogene Therapeutics Inc (NASDAQ:ALLO) is 13.02% up.
The consensus price target for the stock as assigned by Wall Street analysts is 33.5, meaning bulls need an upside of 93.52% from its current market value. According to analyst projections, ALLO’s forecast low is 7 with 55 as the target high. To hit the forecast high, the stock’s price needs a -2434.56% plunge from its current level, while the stock would need to soar -222.58% for it to hit the projected low.
Allogene Therapeutics Inc (ALLO) estimates and forecasts
Year-over-year growth is forecast to reach -68.42% down from the last financial year.
Consensus estimates given by 16 financial analysts project the company’s revenue in the current quarter to hit an average of 10.5k. 12 analysts are of the opinion that Allogene Therapeutics Inc’s revenue for the current quarter will be 4.17k. The company’s revenue for the corresponding quarters a year ago was 21k and 22k respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -50.00%. The estimates for the next quarter sales put growth at -81.05%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 22.18%. The 2025 estimates are for Allogene Therapeutics Inc earnings to increase by 36.25%, but the outlook for the next 5-year period is at 11.41% per year.
Allogene Therapeutics Inc (NASDAQ:ALLO)’s Major holders
TPG GP A, LLC holds the second largest percentage of outstanding shares, with 9.8493% or 18.72 million shares worth $43.61 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Smallcap World Fund and Vanguard Total Stock Market Index Fund. With 6.9 shares estimated at $14.97 million under it, the former controlled 3.29% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 2.07% of the shares, roughly 4.34 shares worth around $9.41 million.
